LYEL CLUSTER SEC Filing Analysis

Final — all horizons settled through T+60d ⚠ clustered

LYEL ▼ -23.64% at T+60d

LONG call ✗ call lost -23.64% · α vs SPY -36.42% · entry $22.46 → $17.15

Last close $13.50 (close Jun 12) · -39.89% from $22.46 entry

Entry anchored
Mar 5, 03:59 PM ET
via Databento tick

T+1d

+13.54%

call +13.54% · α +12.69%

$25.50

settled 3mo ago

T+5d

-5.39%

call -5.39% · α -3.86%

$21.25

settled 3mo ago

T+20d

-3.43%

call -3.43% · α -1.38%

$21.69

settled 2mo ago

T+60d

-23.64%

call -23.64% · α -36.42%

$17.15

settled 14d ago

Price Chart

Loading chart...

Executive Summary

Two funds affiliated with ARCH Venture Partners collectively purchased nearly $25 million worth of Lyell Immunopharma shares in open-market transactions at $25.61 per share. This represents a significant, coordinated investment by a major biotech venture firm, signaling strong confidence in the company's future prospects.

Key Financial Metrics

Direction

buying

Total Value

$25.0M

Insiders

2

Actionable Insight

This level of coordinated buying by a sophisticated biotech investor like ARCH Venture Partners is highly unusual and suggests strong conviction ahead of potential clinical or strategic developments. Traders should watch for upcoming catalysts such as trial readouts, partnerships, or funding news.

Key Facts

ARCH Venture Partners IX, LLC purchased 488,090 shares at $25.61 for $12,500,000
ARCH Venture Fund XIII, L.P. purchased 488,090 shares at $25.61 for $12,500,000
Total open-market purchases: $25.0M across two affiliated funds
Transactions occurred on 2026-03-06 in a single day
Combined purchase represents approximately 5.2% of Lyell's $477M market cap

Financial Impact

$25.0 million in insider buying, equivalent to 5.2% of market capitalization

market sentimentshare ownershipinvestor confidence

Risk Factors

The purchases were made by affiliated funds, not company insiders (executives or directors), so this reflects investor confidence rather than direct management sentiment
Biotech stocks are inherently volatile and sensitive to clinical trial outcomes

Market Snapshot

Exchange

Nasdaq

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

Document	Accession Number
CONTEXT: Insider Cluster Data (2 trades, 7d window)	cluster-LYEL-1773088624224

10 reports for LYEL

T+1T+5T+20T+60

Filters

Reports for LYEL — sortable, filterable
	Type				Now
Jun 12, 2026 2d ago	Press Release NEUTRAL ★ 4/10	$13.32 awaiting T+20	awaiting T+20	—	$13.50 (+1.39%)
Jun 8, 2026 6d ago	Press Release BULLISH ★ 7/10	$11.94 awaiting T+20	awaiting T+20	—	$13.50 (+13.11%)
Jun 4, 2026 10d ago	Press Release NEUTRAL ★ 3/10	$13.02 awaiting T+20	awaiting T+20	—	$13.50 (+3.73%)
Apr 24, 2026 7w ago	DEFA14A NEUTRAL ★ 3/10	$22.62 $16.37	▼ −27.63%	▼ −32.59%	$13.50 (−40.32%)
Apr 15, 2026 8w ago	EFFECT NEUTRAL ★ 2/10	$23.84 $19.25	▼ −19.25%	▼ −25.30%	$13.50 (−43.37%)
Apr 3, 2026 10w ago	S-3 NEUTRAL ★ 2/10	$21.69 $20.72	▼ −4.47%	▼ −13.45%	$13.50 (−37.76%)
Mar 12, 2026 13w ago	Press Release MIXED ★ 6/10	$21.25 $24.80	▲ +16.71%	▲ +13.12%	$13.50 (−36.47%)
Mar 9, 2026 13w ago	Press Release NEUTRAL ★ 5/10	$25.50 $21.78	▼ −14.59%	▼ −11.78%	$13.50 (−47.06%)
Mar 6, 2026 14w ago	Insider Cluster BULLISH ★ 8/10	$22.46 $21.69	▼ −3.43%	▼ −1.38%	$13.50 (−39.89%)
Feb 28, 2026 15w ago	Institutional Cluster MIXED ★ 5/10	$24.10 $19.29	▼ −19.96%	▼ −12.02%	$13.50 (−43.98%)

US Market Status

Market Closed — Opens in 5h 7m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access